Two More Pairs of Denosumab Biosimilars Enter US Market

The Top 5 Biosimilar Articles for the Week of October 30

November 3rd 2023

By Skylar Jeremias

Here are the top 5 biosimilar articles for the week of October 30, 2023.

Physicians Agree on Safety of Biosimilars, Nonmedical Switching in IBD, Survey Says

November 2nd 2023

By Skylar Jeremias

An international survey found that providers agree that use of biosimilars in inflammatory bowel disease (IBD) is safe and effective in both patients who are treatment-naïve and those who are already being treated with a reference agent.

FDA Approves First Stelara Biosimilar, Wezlana

November 1st 2023

By Skylar Jeremias

The FDA approved Amgen’s Wezlana (ustekinumab-auub) as the first biosimilar to reference Stelara (ustekinumab). The biosimilar was also approved with an interchangeability designation.

Biosimilars Business Roundup: October 2023

November 1st 2023

By Skylar Jeremias

Between 3 regulatory approvals, 2 complete response letters, and new data and industry insights, October brought a number of business updates that have the potential to impact the entire US biosimilar industry.

Provider Acceptance Driving Confidence in Biosimilar Therapy

October 31st 2023

Providers speak to the importance of being knowledgeable of efficacy and safety data before prescribing biosimilars to patients.

Navigating Challenges Associated with Biosimilars Across Various Disease States

October 31st 2023

Clinical and social challenges associated with biosimilars are discussed by key opinion leaders.

Pegfilgrastim Biosimilar Proves Effective Against Neutropenia in Patients With Breast Cancer

October 31st 2023

By Skylar Jeremias

A recent study found that a pegfilgrastim biosimilar was effective against chemotherapy-induced neutropenia and had comparable safety and efficacy profiles compared with the originator (Neulasta) in patients with breast cancer.

Dr Ivo Abraham Column: Not All Quiet on the Biologics Front—Biosimilars, Biobetters, and Bioparallels

October 30th 2023

By Ivo Abraham, PhD

In his comeback column, Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, explores the world of biobetters and the complicated dynamics surrounding the FDA approval of Zymfentra, the first subcutaneous infliximab.

Dr Stephen Hanauer Gives Insight Into Growing US Adalimumab Market

October 29th 2023

By Skylar Jeremias

Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, reflects on data concerning the potential for adalimumab biosimilars to gain significant market share.

Commercial Biosimilar Coverage Is on the Rise, but Preferences Still Vary

October 28th 2023

By Skylar Jeremias

A poster from AMCP Nexus quantifies trends in biosimilar coverage within Tufts Medical Center, finding that payer coverage of these products has increased but individual preferences among payers still vary.